|
EAM-2201
EAM-2201 (4'-ethyl-AM-2201, 5"-fluoro-JWH-210, SGT-14) is a drug that presumably acts as a potent agonist for the cannabinoid receptors. It had never previously been reported in the scientific or patent literature, and was first identified by laboratories in Japan in July 2012 as an ingredient in synthetic cannabis smoking blends Like the closely related MAM-2201 which had been first reported around a year earlier, EAM-2201 thus appears to be another novel compound invented by designer drug suppliers specifically for recreational use. Structurally, EAM-2201 is a hybrid of two known cannabinoid compounds JWH-210 and AM-2201, both of which had previously been used as active ingredients in synthetic cannabis blends before being banned in many countries. Pharmacology EAM-2201 acts as a full agonist with a binding affinity of 0.380 nM at CB1 and 0.371 nM at CB2 cannabinoid receptors. Legal status In the United States, all CB1 receptor agonists of the 3-(1-naphthoyl)indole ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Temporary Class Drug
A temporary class drug is a relatively new status for controlled drugs, which has been adopted in some jurisdictions, notably New Zealand and the United Kingdom, to attempt to bring newly synthesised designer drugs under legal control. The controlled drug legislation in these jurisdictions requires drug scheduling decisions to follow an evidence-based process, where the harms of the drug are assessed and reviewed so that an appropriate legal status can be assigned. Since many designer drugs sold in recent years have had little or no published research that could help inform such a decision, they have been widely sold as "legal highs", often for months, before sufficient evidence accumulates to justify placing them on the controlled drug schedules. This situation has been deemed to be undesirable, as every time a designer drug has been banned, novel compounds with similar effects have been quickly developed and brought to market, often with worse health consequences reported than the ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Drugs Controlled By The German Betäubungsmittelgesetz
Drugs controlled by the German ''Betäubungsmittelgesetz'' (BtMG). Trade and drug possession, possession of these substances without licence or prescription is considered illegal; prescription is illegal for drugs on ''Anlage I'' and II and drugs on ''Anlage III'' require a special prescription form. ''Anlage I'' ''Anlage I'' controlled substances are tradability, non-tradable. Those substances are available only by special permission of the authorities, which is granted only for scientific or other public interest purposes. As well as ester, ether, Stereoisomerism, stereoisomers and salts of the substances listed in ''Anlage I''. '' Anlage II'' ''Anlage II'' controlled substances are tradability, tradable, given special permission of the authorities, however not medical prescription , prescriptible. Narcotics on ''Anlage II'' are usually needed for the production of other narcotics on ''Anlage III''. As well as ester, ether and salts of the substances listed in ''Anlage II'' ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
MAM-2201
MAM-2201 (4'-methyl-AM-2201, 5"-fluoro-JWH-122) is a drug that presumably acts as a potent agonist for the cannabinoid receptors. It had never previously been reported in the scientific or patent literature, and was first identified by laboratories in the Netherlands and Germany in June 2011 as an ingredient in synthetic cannabis smoking blends. Like RCS-4 and AB-001, MAM-2201 thus appears to be a novel compound invented by "research chemical" suppliers specifically for grey-market recreational use. Structurally, MAM-2201 is a hybrid of two known cannabinoid compounds JWH-122 and AM-2201, both of which had previously been used as active ingredients in synthetic cannabis blends before being banned in many countries. A study of MAM-2201 in rats showed that it causes neurofunctional disruptions. Legal status In the United States, all CB1 receptor agonists of the 3-(1-naphthoyl)indole class such as MAM-2201 are Schedule I Controlled Substances. MAM-2201 has been banned by being add ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
NM-2201
NM-2201 (also known as CBL-2201) is an indole-based synthetic cannabinoid that presumably has similar properties to the closely related 5F-PB-22 and NNE1, which are both full agonists and unselectively bind to CB1 and CB2 receptors with low nanomolar affinity. Pharmacology NM-2201 acts as a full agonist with a binding affinity of 0.332 nM at CB1 and 0.732 nM at CB2 cannabinoid receptors. It has been linked to serious adverse events in users. Legal status NM-2201 is specifically banned in Sweden, Germany (Anlage II), and Japan but is also controlled in many other jurisdictions under analogue laws. On May 30, 2018 the United States Drug Enforcement Administration, Department of Justice published a notice of intent to place NM-2201 and 4 other synthetic cannabinoids in schedule I of the Controlled Substances Act. This notice went into effect on June 29, 2018. Use NM-2201 was linked to an incident in December 2015 where 25-30 people in Ocala, FL were taken to hos ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Designer Drugs
A designer drug is a structural or functional analog of a controlled substance that has been designed to mimic the pharmacological effects of the original drug, while avoiding classification as illegal and/or detection in standard drug tests. Designer drugs include psychoactive substances that have been designated by the European Union as new psychoactive substances (NPS) as well as analogs of performance-enhancing drugs such as designer steroids. Some of these were originally synthesized by academic or industrial researchers in an effort to discover more potent derivatives with fewer side effects, and shorter duration (and possibly also because it is easier to apply for patents for new molecules) and were later co-opted for recreational use. Other designer drugs were prepared for the first time in clandestine laboratories. Because the efficacy and safety of these substances have not been thoroughly evaluated in animal and human trials, the use of some of these drugs may result i ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Organofluorides
Organofluorine chemistry describes the chemistry of the organofluorines, organic compounds that contain the carbon–fluorine bond. Organofluorine compounds find diverse applications ranging from Lipophobicity, oil and hydrophobe, water repellents to pharmaceuticals, refrigerants, and reagents in catalysis. In addition to these applications, some organofluorine compounds are pollutants because of their contributions to ozone depletion, global warming, bioaccumulation, and toxicity. The area of organofluorine chemistry often requires special techniques associated with the handling of fluorinating agents. The carbon–fluorine bond Fluorine has several distinctive differences from all other substituents encountered in organic molecules. As a result, the physical and chemical properties of organofluorines can be distinctive in comparison to other organohalogens. # The carbon–fluorine bond is one of the strongest in organic chemistry (an average bond energy around 480 kJ/molKirsch ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Naphthoylindoles
Naphthoylindoles are a class of synthetic cannabinoids. See also * Structural scheduling of synthetic cannabinoids To combat the illicit synthetic cannabinoid industry many jurisdictions have created a system to control these cannabinoids through their general (or Markush) structure as opposed to their specific identity. In this way new analogs are already cont ... References {{reflist ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
THJ-2201
THJ-2201 is an indazole-based synthetic cannabinoid that presumably acts as a potent agonist of the CB1 receptor and has been sold online as a designer drug. It is a structural analog of AM-2201 in which the central indole ring has been replaced by indazole. Pharmacology THJ-2201 acts as a full agonist with a binding affinity of 1.34nM at CB1 and 1.32nM at CB2 cannabinoid receptors. Side effects THJ-2201 has been linked to at least one hospitalization and death due to its use. Legal status Because of the hazards associated with recreational use of this compound, it is classified as a Schedule I controlled substance in the United States. It is also an Anlage II controlled drug in Germany. See also * AM-694 * AM-1235 * AM-2232 * AM-2233 * FUBIMINA * JWH-018 * List of AM cannabinoids * List of JWH cannabinoids * NM-2201 * THJ-018 THJ-018 (SGT-17) is a synthetic cannabinoid that is the indazole analogue of JWH-018 and has been sold online as a designer drug. Pharmaco ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
JWH-018
JWH-018 (1-pentyl-3-(1-naphthoyl)indole, NA-PIMO or AM-678) is an analgesic chemical from the naphthoylindole family that acts as a full agonist at both the CB1 and CB2 cannabinoid receptors, with some selectivity for CB2. It produces effects in animals similar to those of tetrahydrocannabinol (THC), a cannabinoid naturally present in cannabis, leading to its use in synthetic cannabis products that in some countries are sold legally as "incense blends". As a full agonist at both the CB1 and CB2 cannabinoid receptors, this chemical compound is classified as an analgesic medication. The analgesic effects of cannabinoid ligands, mediated by CB1 receptors are well established in treatment of neuropathic pain, as well as cancer pain and arthritis. These compounds work by mimicking the body's naturally-produced endocannabinoid hormones such as 2-AG and anandamide (AEA), which are biologically active and can exacerbate or inhibit nerve signaling. As the cause is poorly understood in chr ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
AM-2233
AM-2233 is a drug that acts as a highly potent full agonist for the cannabinoid receptors, with a ''K''i of 1.8 nM at CB1 and 2.2 nM at CB2 as the active (''R'') enantiomer. It was developed as a selective radioligand for the cannabinoid receptors and has been used as its 131I derivative for mapping the distribution of the CB1 receptor in the brain. AM-2233 was found to fully substitute for THC in rats, with a potency lower than that of JWH-018 but higher than WIN 55,212-2. It is notable for inducing tinnitus, though the reasons for this are unclear and may provide valuable insight into tinnitus research. Legal Status As of October 2015 AM-2233 is a controlled substance in China. See also * AM-679 * AM-694 * AM-1220 * AM-1221 * AM-1235 * AM-1241 * AM-2232 * Cannabipiperidiethanone * FUBIMINA * JWH-018 * List of AM cannabinoids * List of JWH cannabinoids * List of HU cannabinoids * List of designer drugs Designer drugs are structural or functional analogues of ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
AM-2232
AM-2232 (1-(4-cyanobutyl)-3-(naphthalen-1-oyl)indole) is a drug that acts as a potent but unselective agonist for the cannabinoid receptors, with a ''K''i of 0.28 nM at CB1 and 1.48 nM at CB2. In the United States, all CB1 receptor agonists of the 3-(1-naphthoyl)indole class such as AM-2232 are Schedule I Controlled Substances. See also * AM-694 * AM-1235 * AM-2233 * FUBIMINA * JWH-018 * List of AM cannabinoids * List of JWH cannabinoids * O-774 * O-1057 * O-1812 * THJ-2201 THJ-2201 is an indazole-based synthetic cannabinoid that presumably acts as a potent agonist of the CB1 receptor and has been sold online as a designer drug. It is a structural analog of AM-2201 in which the central indole ring has been replac ... References Naphthoylindoles Nitriles AM cannabinoids Designer drugs {{cannabinoid-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
AM-1235
AM-1235 (1-(5-fluoropentyl)-3-(naphthalen-1-oyl)-6-nitroindole) is a drug that acts as a potent and reasonably selective agonist for the cannabinoid receptor CB1. Pharmacology Pharmacodynamics AM-1235 is a cannabinoid receptor agonist with Ki of 1.5 nM at CB1 compared to 20.4 nM at CB2. While the 6-nitro substitution on the indole ring reduces affinity for both CB1 and CB2 relative to the unsubstituted parent compound AM-2201, CB2 affinity is reduced much more, resulting in a CB1 selectivity of around 13 times. This is in contrast to other related compounds such as AM-1221 where a 6-nitro substitution instead confers significant selectivity for CB2. Pharmacokinetics AM-1235 metabolism differs only slightly from that of JWH-018. AM-1235 ''N''-dealkylation produces fluoropentane instead of pentane (or plain alkanes in general). It has been speculated that the fluoropentane might function as an alkylating agent or is further metabolized into toxic fluoroacetic acid. ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
